Lumos Diagnostics Holdings Ltd. · ASX:LDX
Lumos Diagnostics — H1 FY2023 Earnings Presentation
20 slides from Lumos Diagnostics's earnings presentation, Mar 6, 2023
Slide 1: ASX Announcement: Updated Investor Presentation
For personal use only ASX ANNOUNCEMENT Updated Investor Presentation MELBOURNE, Australia (6 March 2023) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) is pleased to provide an update version of its investor presentation. This presentation provides an update on the commercial operations
Slide 2: About Lumos Diagnostics; Forward-Looking Statements
About Lumos Diagnostics Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services fo
Slide 3: H1 FY23 Result – Investor Presentation
For personal use only Lumos Diagnostics Holdings Limited H1 FY23 Result – Investor Presentation March 2023 www.lumosdiagnostics.com Confidential. This document and supporting materials contain confidential and proprietary business information from Lumos. 1
Slide 4: Disclaimer and Important Information
Disclaimer and Important Information For personal use only This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company). The information contained in this document (“Document”) has been prepared by Lumos Diagnostics Holdings Lim
Slide 5: Company Overview
Company Overview For personal use only Lumos is a fully-integrated developer and manufacturer of connected, rapid, point-of-care tests for the diagnostics and healthcare industries • Led by Doug Ward, industry veteran with over 30 years experience in diagnostics • Comprehensive offering from concept
Slide 6: Board of Directors
Board of Directors For personal use only Sam Lanyon Bronwyn Le Grice Lawrence Mehren Catherine Robson Executive Chair Non-Executive Non-Executive Non-Executive Director Director Director 4
Slide 7: Highly experienced industry veteran recently appointed
Highly experienced industry veteran recently appointed For personal use only Doug Ward – extensive experience in diagnostics industry • >30-year career in Diagnostics and Life Sciences industries • Roles with Roche/Ventana Medical, GE, Siemens, Bayer, Chiron, PGDX and Hologic which included: - Expan
Slide 8: Favourable industry structure and key trends
Favourable industry structure and key trends For personal use only Robust underlying category growth forecast GLOBAL POC DIAGNOSTIC TEST SALES • Significant growth anticipated from growing role of diagnostic tests in healthcare • Rapid, point-of-care tests increasingly being used – common in US sett
Slide 9: Lumos has a compelling and highly competitive offering
Lumos has a compelling and highly competitive offering For personal use only 1. Fully-integrated—from design to manufacturing 2. Proprietary reader platform for use in different settings Strategic Product Commercial Innovation Development Manufacturing Single-use Multi-use disposable Desktop readers
Slide 10: Lumos' POC diagnostic test development engine
Lumos’ POC diagnostic test development engine For personal use only Design Develop Manufacture Product concepts REVENUE Contract Fees Margin Sales & license payments STREAMS from services from manufacturing from own products 8
Slide 11: Strategic partnerships are a key pillar of Lumos' growth plan
Strategic partnerships are a key pillar of Lumos’ growth plan For personal use only Lumos provides a compelling service offering for leading diagnostics companies • Fully-integrated offering—from concept-to-clinic-to-commercial production • Proprietary reader platform—integrate POC testing with elec
Slide 12: Lumos has established a strategic relationship with Hologic
Lumos has established a strategic relationship with Hologic For personal use only • Hologic is a recognized global leader in women’s health based in Massachusetts - NASDAQ: HOLX, Market Capitalization US$20 billion - FY2022 revenue of US$4.2 billion with net income of US$1.3 billion - Diagnostic pro
Slide 13: FebriDx – Lumos' POC test to aid antibiotic prescribing
FebriDx – Lumos’ POC test to aid antibiotic prescribing For personal use only • FebriDx offers an aid for healthcare providers to improve patient care and antibiotic stewardship - 211 million outpatient antibiotic prescriptions in the US in 20211 - 30% antibiotics prescribed in outpatient settings u
Slide 14: ViraDx – Lumos' POC test for key respiratory infections
ViraDx – Lumos’ POC test for key respiratory infections For personal use only • ViraDx highly relevant POC test for post-pandemic environment: - SARS-CoV-2 pandemic increased consumer and healthcare POC testing - ViraDx is a 3-in-1 test for COVID-19/’flu A/’flu B • ViraDx regulatory and commercial u
Slide 15: H1 FY23 Result
For personal use only H1 FY23 Result
Slide 16: 1H FY23 – Result Highlights
1H FY23 – Result Highlights* For personal use only “ While Lumos went into FY2023 Half year revenue steady at $5.1 million ($5.2 million: H1 FY22); revenue from services up 6% pcp facing a number of challenges, Successful restructuring and consolidation of operations to a single US site in Carlsbad,
Slide 17: Revenue & Gross Profit
Revenue & Gross Profit For personal use only (US$ in thousands) REVENUE REVENUE MIX GROSS PROFIT $6,428 100% $6,000 $3,000 60% $5,202 $5,087 $2,401 $2,501 $5,000 80% $2,500 50% 46% $2,055 49% $4,000 60% $2,000 40% $3,000 $1,500 32% 30% 40% $2,000 $1,000 20% 20% $1,000 $500 10% 0% $0 $0 0% 1H FY22 2H
Slide 18: OPEX & EBITDA
OPEX & EBITDA For personal use only (US$ in thousands) OPERATING EXPENSES1 EBITDA2 NPAT3 1H FY22 2H FY22 1H FY23 $14,000 $12,173 $0 $12,000 $10,533 -$2,000 Underlying EBITDA Loss (3,715) $10,000 Dep'n & Amortization (2,030) $8,000 $6,216 -$4,000 -$3,715 Impairments: $6,000 -$6,000 Inventory (542) $4
Slide 19: Promising Outlook
Promising Outlook For personal use only “ There is little doubt in my mind that POC diagnostic tests are Expand and diversify pipeline of commercial services projects going to become an ever- increasing part of our lives. Continue to build foundation for long-term growth through strategic partnershi
Slide 20: For personal use only
For personal use only www.lumosdiagnostics.com 18
Lumos Diagnostics Holdings — H1 FY2023 Earnings Presentation on 6ix